LAV

LAV is a global biomedical venture capital firm founded in 2008 as a corporate venture subsidiary of Eli Lilly. It became an independent investment management company in 2011. With offices in Hong Kong, Shanghai, and Palo Alto, LAV focuses on partnering with exceptional entrepreneurs to build companies that develop breakthrough products aimed at treating diseases and improving human health.

The firm’s investment philosophy centers on long-term thinking, betting on people, products, and quality science. LAV is highly selective, supporting entrepreneurs with ambition, leadership, and integrity by providing smart capital and strategic value such as executive recruitment, industry connections, and business development opportunities. The firm avoids low-quality or hype-driven investments, focusing instead on sustainable companies with science-based, high-quality products.

LAV’s team comprises over 50 professionals with deep expertise in science, medicine, investment, and operations. They leverage significant biomedical resources, regulatory knowledge, and global market insights to support portfolio companies. Their vision is to catalyze global medical innovations and meet the growing demand for better healthcare through long-term partnerships and investments.